Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.
about
Pulmonary arterial hypertension: the clinical syndrome.Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challengesFrom short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertensionAre hemodynamics surrogate end points in pulmonary arterial hypertension?Quality of life as a prognostic marker in pulmonary arterial hypertensionTwo-dimensional echocardiography in the assessment of long-term prognosis in patients with pulmonary arterial hypertensionSex differences in response to tadalafil in pulmonary arterial hypertension.Value of impedance cardiography during 6-minute walk test in pulmonary hypertension.Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial HypertensionEfficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension.Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening.Riociguat for pulmonary arterial hypertension associated with congenital heart disease.Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.Pulmonary vascular remodeling and right heart failure in pulmonary hypertension: future role of positron emission tomography in decoding the enigma.Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension.Updating clinical endpoint definitions.Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparisonAdverse Events in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.Physical Activity and Symptoms in Pulmonary Arterial Hypertension.Endoscopic ulcers as a surrogate marker of NSAID-induced mucosal damage.Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy.Six-minute walk test in pulmonary arterial hypertensionThe COPD Biomarker Qualification Consortium (CBQC).Update in pulmonary vascular diseases 2012.Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?Beyond right ventricular size and function: the importance of evaluating the right ventricle's capacity for recovery.Riociguat: a novel new drug for treatment of pulmonary hypertension.Biomarkers and prognostic indicators in pulmonary arterial hypertension.Development of macitentan for the treatment of pulmonary arterial hypertension.A Contemporary Approach to Pulmonary Arterial Hypertension.Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension.Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension.Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension.Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial.A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints.
P2860
Q30583630-95740289-F5D2-4147-8A4E-88F0EFE105E7Q33596457-51271803-3430-4CA8-AFF2-1DD3EB4404AFQ33788582-BB198F93-CFC8-4FFD-A169-72B6D7A0ACC9Q33806102-97E7FC01-DCC5-4E6D-9535-FDB980E9E546Q34098418-2ECEE177-9F90-48E6-BF94-3E10E28B30E4Q34207690-ACF9D532-A75A-493C-BC0A-95BC5B052908Q34653817-3F3B1BE5-3072-413E-91B0-24BE9E2FFDE3Q34840330-D2D1C3F3-D948-4781-A2B5-387F2A353BC0Q34865736-EDE4AE59-6B45-49C1-9DDB-71103CBE854FQ34985436-686CEB3C-BD43-4393-843D-EB43215B2F3BQ35620058-A41C2A84-E42D-4E78-A4F4-11AEF10F5732Q36272410-B03E5177-7AF0-4D51-8D8A-A7394887F54AQ36287760-AC75FA8B-BAB8-4E26-AB64-C3EB8E564103Q36352106-66A73FE9-6F16-40A6-A8B2-B65D24691800Q36374793-4D036776-F571-4CD1-A4BD-F0BB568B9CA4Q36411409-04166370-5A3E-4649-8607-D981F8C6863DQ36468672-4F6DE04D-870E-42B2-A685-0226BC7EE8F6Q36490169-438E5CB9-656B-4968-9DF8-82FDE1CFB49BQ36810813-D2E1C0B8-0636-4C06-A7EB-9E2214884A59Q36982785-AFBE8292-CED9-44A3-AE2B-869590A6E573Q37106203-1F7DD41A-8A25-42F7-B55B-1E52CF09A119Q37166393-CEE3DFDC-FE30-4269-BF22-7CAF0C2B7FD5Q37476761-117773B1-6D4B-4999-BAD0-1ABA17A7DD50Q37555376-B30A4601-98DD-4B25-B3F2-3FBB42EE04EBQ37680689-16941E9E-9604-402B-8A98-E102557E53BBQ38109909-FFDD2EE4-9197-4626-B1C3-67C31BB890EAQ38118390-33A7111D-334A-4B7E-B413-3DB39154B3F9Q38164816-2106C81A-A87C-4352-9C10-03AD3CE7CD2DQ38233856-39E6FC7F-F69F-4FBE-8197-6CD14F76C85CQ38255148-AD336660-99F3-445F-8A5E-08A893CB91CCQ38502798-F18810F2-E933-4BBA-A6C0-4D959090BBA8Q38520683-15DDA5E9-A293-4719-95E4-6B47A24DE36BQ38570060-25ED8996-F353-4AE6-B517-CC334EF4DCE6Q38834511-AF42354C-EC55-46DF-A87B-B381B06698FCQ38859147-CBF311E1-6176-4E6E-9DE0-7976F6394C70Q38896631-C1F0AD82-7B7B-4BC0-847C-8813541DD81DQ38923215-9B42C616-E592-41AE-8A8E-4BE50CC93BDBQ40591652-F8C74A60-A4AF-4FD4-93B7-12F5EB1A86E8Q41435645-004FF076-D9EC-4EEB-8140-BFD00DAA3395Q41484464-8A727DE1-F518-4293-98D4-6038881549B9
P2860
Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Validation of 6-minute walk di ...... arterial hypertension trials.
@ast
Validation of 6-minute walk di ...... arterial hypertension trials.
@en
Validation of 6-minute walk di ...... arterial hypertension trials.
@nl
type
label
Validation of 6-minute walk di ...... arterial hypertension trials.
@ast
Validation of 6-minute walk di ...... arterial hypertension trials.
@en
Validation of 6-minute walk di ...... arterial hypertension trials.
@nl
prefLabel
Validation of 6-minute walk di ...... arterial hypertension trials.
@ast
Validation of 6-minute walk di ...... arterial hypertension trials.
@en
Validation of 6-minute walk di ...... arterial hypertension trials.
@nl
P2093
P2860
P1433
P1476
Validation of 6-minute walk di ...... arterial hypertension trials.
@en
P2093
Benjamin French
Brian L Strom
Harold I Palevsky
Nicole B Gabler
Scott D Halpern
Steven M Kawut
P2860
P304
P356
10.1161/CIRCULATIONAHA.112.105890
P407
P577
2012-06-13T00:00:00Z